• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Does 10x Genomics' (TXG) Russell Value Index Exit Reveal About Its Evolving Investor Base?

    Simply Wall St·07/05/2026 15:24:05
    Listen to the news
    • In late June 2026, 10x Genomics, Inc. was removed from several Russell value benchmarks, including the Russell 2000 Value and Russell 3000 Value indexes.
    • This broad index exclusion can matter for investors because it often triggers selling by index-tracking funds, altering trading flows without any direct change to the company’s operations.
    • We’ll explore how 10x Genomics’ removal from multiple Russell value indexes may influence its existing investment narrative built around product expansion and funding risks.

    Find 44 companies with promising cash flow potential yet trading below their fair value.

    10x Genomics Investment Narrative Recap

    To stay invested in 10x Genomics, you need to believe its single cell and spatial biology platforms can convert scientific buzz into durable, recurring consumables revenue, despite ongoing losses and funding uncertainty. The recent removal from multiple Russell value indexes may influence short term trading and sentiment, but it does not directly change the immediate catalysts around product adoption or the key risk that research budgets and pricing pressures could weigh on revenue and delay a path toward earnings stability.

    Against that backdrop, the April 2026 launch of Atera, a new in situ spatial biology platform with pre orders already open, is especially relevant. It reinforces the product expansion narrative that underpins expectations for higher consumables use over time, while also reminding investors that each new platform adds complexity and cost. How quickly Atera adoption ramps, relative to persistent funding and margin pressures, sits at the heart of the near term risk reward trade off for 10x Genomics shareholders.

    Yet behind the product story, there is a less obvious funding and budget risk that investors should be aware of, particularly if government grants...

    Read the full narrative on 10x Genomics (it's free!)

    10x Genomics' narrative projects $709.8 million revenue and $110.2 million earnings by 2029. This requires 3.4% yearly revenue growth and a $153.7 million earnings increase from -$43.5 million today.

    Uncover how 10x Genomics' forecasts yield a $20.14 fair value, a 48% downside to its current price.

    Exploring Other Perspectives

    TXG 1-Year Stock Price Chart
    TXG 1-Year Stock Price Chart

    Compared with the baseline view, the lowest analysts were far more cautious, assuming only about 2.7 percent annual revenue growth and no profitability within three years, so you should treat the index exclusion as one more factor that might prompt you to recheck which version of the story you find more realistic.

    Explore 3 other fair value estimates on 10x Genomics - why the stock might be worth 48% less than the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Curious About Other Options?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.